Tumor Biology Program

项目摘要-肿瘤生物学计划 肿瘤生物学计划是阿布拉姆森癌症中心的两个基础科学研究计划之一 (ACC)。该计划旨在促进行政协调委员会内的研究，以促进对机制的理解 潜在的肿瘤发生机制，并确定将使新的预防、诊断、预后和 癌症的治疗方法。自20世纪70年代初成立以来，肿瘤生物学计划已经 继续对癌症研究的新兴领域和进展作出反应。该计划目前正在组织中 围绕三个中心目标：1)阐明癌症的分子和细胞基础；2)了解 肿瘤的表观遗传学；3)研究肿瘤的微环境和转移进展。成员： 肿瘤生物学是高度互动的，在与以下方面相关的科学主题上以程序内的方式进行协作 每个目标包括基因组完整性、细胞信号、新陈代谢和病毒途径，并着眼于 在我们的集水区，负担或健康差距最大。肿瘤生物学的突破性发现 发现上皮-间充质转化的新机制，癌症药物的转录调控 敏感性，炎症的表观遗传调节，前列腺癌雄激素抵抗的新机制， 以及通过病毒模仿进行免疫逃避。与其他人合作，将新的目标转移到诊所 早期发现和治疗方案。肿瘤生物学学科由充满活力的新学科带头 共同领导(请)雪莉·伯杰博士和桑德拉·瑞姆博士，他们共同催化了有影响力的内部和 通过各种创新方法进行程序间协作。PLS在招聘过程中起到了重要作用 新成员，指导初级教员，促进教员之间的互动和会议，以及 组织会议和座谈会。肿瘤生物学项目成员在培训和培训中发挥着关键作用 指导高中生、博士生、医学博士研究生和医学博士或博士后研究员 通过他们在宾夕法尼亚大学生物医学研究生中的领导作用进行癌症相关研究 研究(BGS)、MD/PHD计划(MSTP)和NIH T32培训补助金。肿瘤的持续成功 生物学计划的成员取得的非凡科学进步证明了这一点，通过 具有多机构、计划间和计划内协作的高影响力出版物，提供关键 对癌症生物学的洞察。目前，该方案有来自20个部门和5个部门的53名成员 不同的学校，资金总额为2570万美元(年度直接成本)，其中2000万美元为同行评议，640万美元 是由NCI资助的。该计划有67个R01等价物。自2015年以来，肿瘤生物学计划成员发表 617篇与癌症相关的论文，其中15%是程序内的，29%是程序间的，62%是程序间的 都是多机构的。

PROJECT SUMMARY – Tumor Biology Program The Tumor Biology Program is one of two basic science Research Programs of the Abramson Cancer Center (ACC). This Program aims to catalyze research within the ACC to advance an understanding of mechanisms underlying tumorigenesis and to identify pathways that will enable novel preventive, diagnostic, prognostic and therapeutic approaches to cancer. Since its inception in the early 1970s, the Tumor Biology Program has continued to respond to emerging areas and advances in cancer research. The Program is currently organized around three central Aims: 1) Elucidate the molecular and cellular basis underlying cancer; 2) Understand the epigenetics of cancer; and 3) Investigate the tumor microenvironment and metastatic progression. Members of Tumor Biology are highly interactive, collaborating intra-Programmatically across scientific topics relevant to each Aim including genome integrity, cell signaling, metabolism, and viral pathways, with an eye on cancers of highest burden or health disparity in our catchment area. Ground-breaking discoveries in Tumor Biology uncovered novel mechanisms of epithelial-mesenchymal transition, transcriptional control of cancer drug sensitivity, epigenetic regulation of inflammation, novel mechanisms of androgen-resistance in prostate cancer, and immune evasion by viral mimicry. New targets were translated to the clinic in collaboration with other Programs for early detection and treatment. The Tumor Biology Program is led by new and energetic Program co-Leaders (PLs) Shelley Berger, PhD and Sandra Ryeom, PhD, who together catalyze impactful intra- and inter-Programmatic collaborations by a variety of innovative methods. The PLs are instrumental in recruiting new members, mentoring junior faculty, stimulating interactions and meetings among faculty members, and organizing conferences and symposia. Tumor Biology Program members play key roles in the training and mentorship of high school students, PhD students, MD/PhD students, and MD or PhD postdoctoral fellows in cancer-related research through their leadership roles in the University of Pennsylvania Biomedical Graduate Studies (BGS), MD/PhD program (MSTP) and NIH T32 training grants. The continued success of the Tumor Biology Program is evidenced by the exceptional scientific progress of its members, demonstrated through high-impact publications with multi-institutional, inter- and intra-Programmatic collaborations, offering key insights into the biology of cancer. Currently, the Program has 53 members from 20 departments and five different schools with total funding of $25.7M (annual direct costs) of which 20.0M is peer-reviewed and $6.4M is NCI-funded. The Program has 67 R01-equivalents. Since 2015, Tumor Biology Program members published 617 cancer-related papers, of which 15% were intra-Programmatic, 29% were inter-Programmatic, and 62% were multi-institutional.